2018 American Society of Clinical Oncology Annual Meeting*

ASCO 2018 Program Image
Download All
June 1-5, 2018; Chicago, Illinois
This program provides coverage of the 2018 ASCO annual meeting with summary slidesets and expert analyses of key results in gastrointestinal cancers, gynecologic cancers, skin cancer, cancer immunotherapy, genitourinary cancers, hematologic malignancies, breast cancer, and lung cancer.

Gastrointestinal Cancer

Capsule Summary Slidesets

Ramucirumab showed a significant survival benefit in patients with advanced HCC and a baseline AFP ≥ 400 mg/mL following previous sorafenib treatment.

Released: June 8, 2018

Final analysis of phase III trial showed no significant improvement with pembrolizumab vs paclitaxel in OS, PFS, or response in patients with previously treated gastric/GEJ cancer and PD-L1 CPS ≥ 1.

Released: June 12, 2018

Lenvatinib combined with pembrolizumab showed promising antitumor activity with no unexpected toxicities in this early-stage study.

Released: June 7, 2018

A modified FOLFIRINOX regimen was superior to gemcitabine after resection of pancreatic cancer, with significantly prolonged disease-free, metastasis-free, and overall survivals.

Released: June 12, 2018

Neoadjuvant treatment extended OS, DFS, and improved R0 resection rate vs adjuvant treatment in patients undergoing surgery for pancreatic cancer.

Released: June 11, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings